Phase 1 N=90 A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers
Asthma
Primary: AUC0-t of Budesonide With and Without Charcoal Blockade — 1870; 1360; 1810; 1330 pg*h/mL — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=150 A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
Dry Eye
Primary: Coprimary Endpoint: Change From Baseline in Inferior Corneal Staining Score to Day 57 (Pre-CAE) — 1.94; 1.96; 1.95; 0.10 score on a scale — p=0.3378
Phase 1 N=27 A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046
Contraception
Primary: Number of Participants With Injection Site Reactions (ISRs) (Excluding Injection Site Pain) — 12; 6; 0; 8 Participants
N/A N=10 Holding, Stress, and Bonding During Therapeutic Hypothermia
Hypoxic-Ischemic Encephalopathy
Primary: Frequency of Adverse Events (Safety) — 0 Participants
Phase 1 N=8 A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088
Healthy Volunteers
Primary: Number of Participants With Treatment Emergent Adverse Events Per Group — 1; 0; 1; 1 Participants
Phase 2 N=30 H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
Avian Influenza · H1N1 Influenza · Influenza
Primary: Percentage of Participants Achieving Seroconversion Based on HAI Titer (A/H7N9 Vaccine, With and Without Adjuvant) — 80.0; 0 percentage of participants
Phase 1 N=91 Clinical Study to Evaluate Z7200 Pharmacokinetics Profile
Asthma
Primary: AUC0-last of Budesonide With and Without Charcoal Blockade — 1710; 1710; 1570; 1530 pg*h/mL — p=<0.001
Phase 2 N=9 Minocycline to Treat Branch Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Mean Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at 12 Months Compared to Baseline. — 5.3; 13.0 ETDRS letters
N/A N=86 Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study
Pregnancy Preterm · Neonatal Hypoglycemia · Hyperglycemia Drug Induced
Primary: Umbilical Cord Blood C-peptide — 1.02; 1.09 ng/mL — p=0.97
Phase 2 N=14 A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
N/A N=916 Comparative Effectiveness Research in Veterans With PTSD
Post-Traumatic Stress Disorder
Primary: Change in PTSD Symptom Severity on the Clinician-Administered PTSD Scale (CAPS) — 24.3; 27.2; 26.4; 28.7 score on a scale
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
Phase 2 N=251 Controlled Study to Assess the Efficacy and Safety of S-Ibuprofen Topical Gel 5% (AP0302) in the Treatment of DOMS
Pain, Acute
Primary: Sum of the Time-weighted Differences From Baseline in Pain Intensity With Movement(SPIDMOVE) Over 24 Hours Post Time Zero — -33.09; -29.09 score on a scale*hours…
N/A N=107 Modifications in the Eating Habits of Adolescents of Secondary Education as a Result of a Nutritional Intervention
Food Habits
Primary: Change in the Consumption of Fruits and Vegetables in the Short Term — 1.1; 0.3 portions / day
N/A N=1,186 SDM for Stroke Prevention in Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Clinician Satisfied Encounters — 277; 400 encounters